Boston Scientific price target lowered to $80 from $90 at BTIG

BTIG lowered the firm’s price target on Boston Scientific (BSX) to $80 from $90 and keeps a Buy rating on the shares. The shares rallied Wednesday on a guidance resets that assumes a pulsed field ablation market share loss, slower Watchman growth, and a longer Urology recovery path, the analyst tells investors in a research note. The firm added that this is an outlook that it views as reasonable and achievable, adding that this reset brings expectations to a level Boston Scientific can credibly execute against.